You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
格隆汇港股聚焦(9.02)︱碧桂园、万科8月销售额同比增逾三成
格隆汇 09-02 23:05

【财务数据

数码通电讯(00315.HK)19/20财年纯利跌40.06%至3.79亿港元 末期息15港仙

【运营数据】

碧桂园(02007.HK):8月权益合同销售额609.3亿元 同比增加30.10%

 万科企业(02202.HK)8月单月销售587.2亿元 同比增长33.06%

美的置业(03990.HK)前8个月销售额718.2亿元 同比增长18.3%

中国奥园(03883.HK)8月物业合同销售额同比增长41%至108.5亿元

金地商置(00535.HK)8月销售额达64.14亿元 同比增长28.3%

合景泰富集团(01813.HK)8月预售额同比增加55.8%至96.12亿元

景瑞控股(01862.HK)8月实现签约销售额35.17亿元 同比增长76.3%

协合新能源(00182.HK)8月权益发电量增长10.32%至311.45GWh

【增减持】

睿见教育(06068.HK)控股股东刘学斌增持190万股

【股本重组】

中国上城(02330.HK)建议“10合1”并股 拟配发7.2亿股筹资7140万港元

并购出售】

美图公司(01357.HK)拟3.59亿元收购厦门美峰科创公园物业

励晶太平洋(00575.HK)拟379万美元收购DLI全部股权进军保健养生领域

天伦燃气(01600.HK)拟1.08亿元收购子洲县顺祥天然气100%股权

【增发供股】

雅高控股(03313.HK)拟配售最多2.22亿股筹资2150万港元

满地科技股份(01400.HK)拟折让12.3%配股 最多筹865万港元

泰格医药(03347.HK)悉数行使超额配股权发行1605.97万股H股

【重大事项】

中国生物制药(01177.HK):治疗纤维化创新药“TDI01”临试申请获CDE受理

百宏实业(02299.HK):百宏高新拟投资3.2亿美元拓展聚酯薄膜业务

东阳光药(01558.HK)H股全流通计划完成

国药科技股份(08156.HK)拟在香港以天祥公证行名义设立及营运口罩检测实验室

虎都(02399.HK)与HAFG订立合作意向书

洛阳钼业(03993.HK)拟以5000万美元参与认购投资基金份额

锦江资本(02006.HK):锦江酒店拟定增募资不超50亿元

白云山(00874.HK):收到药品再注册批准通知书

向中国际(01871.HK)拟出资500万元成立合营投资河南热电产业

【回购注销】

复星国际(00656.HK)9月2日耗资2586万港元回购300万股

石四药集团(02005.HK)9月2日耗资672.6万港元回购134.2万股

合生创展集团(00754.HK)9月2日耗资1998万港元回购129万股

中国旺旺(00151.HK)9月2日耗资2342.05万港元回购434.9万股

金鹰商贸集团(03308.HK)9月2日耗资272万港元回购38.1万股

富智康集团(02038.HK)9月2日耗资133.85万港元回购146.1万股

DYNAM JAPAN(06889.HK)9月2日耗资319.07万港元回购40.46万股

百奥家庭互动(02100.HK)9月2日耗资242.52万港元回购220万股

中国水务(00855.HK)9月2日耗资152万港元回购24.4万股

康臣药业(01681.HK)9月2日耗资162.83万港元回购50万股

【股权激励】

百济神州(06160.HK)授出可认购1080股美国存托股份的购股权

中国生物科技服务(08037.HK)授出966万份购股权

羚邦集团(02230.HK)9月2日授出110.5万股奖励股份

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account